The reduction of the IGF-I/IGFBP-3 ratio in NSCLC patients who responded to first-line treatment suggested such a metric could be a valuable predictor of response to chemotherapy in these patients [65]. The gene discussed is IGF1; the disease is non-small cell lung carcinoma.